Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hernando

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2018
Early evolutionary divergence between papillary and anaplastic thyroid cancersJ Capdevila, R Mayor, F M Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Early evolutionary divergence between papillary and anaplastic thyroid cancersJ Capdevila, R Mayor, F M Mancuso, et al.
RSC Chemical Biology|March 8, 2024
Sialic acids in infection and their potential use in detection and protection against pathogensSimone Dedola, Sanaz Ahmadipour, Peterson de Andrade, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 16, 2016
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumorsA Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela, et al.
ESMO Open|March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RETJ Hadoux, J Hernando, K H Wong, et al.
Nature Communications|May 23, 2023
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung originJ Capdevila, J Hernando, A Teule, et al.
The Oncologist|June 15, 2026
Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?J López-Robles, M Mitjavila, P Jimenez-Fonseca, et al.
ESMO Open|December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trialJ Capdevila, S Tafuto, M Krogh, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2018
Early evolutionary divergence between papillary and anaplastic thyroid cancersJ Capdevila, R Mayor, F M Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Early evolutionary divergence between papillary and anaplastic thyroid cancersJ Capdevila, R Mayor, F M Mancuso, et al.
RSC Chemical Biology|March 8, 2024
Sialic acids in infection and their potential use in detection and protection against pathogensSimone Dedola, Sanaz Ahmadipour, Peterson de Andrade, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 16, 2016
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumorsA Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela, et al.
ESMO Open|March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RETJ Hadoux, J Hernando, K H Wong, et al.
Nature Communications|May 23, 2023
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung originJ Capdevila, J Hernando, A Teule, et al.
The Oncologist|June 15, 2026
Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?J López-Robles, M Mitjavila, P Jimenez-Fonseca, et al.
ESMO Open|December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trialJ Capdevila, S Tafuto, M Krogh, et al.
Pageof 4